<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814840</url>
  </required_header>
  <id_info>
    <org_study_id>SilesianCHD-KNW-6501-3/08</org_study_id>
    <nct_id>NCT00814840</nct_id>
  </id_info>
  <brief_title>Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure</brief_title>
  <acronym>TRUST CRT</acronym>
  <official_title>Triple-Site Versus Standard Cardiac Resynchronization Therapy (TRUST CRT) Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silesian Centre for Heart Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silesian Centre for Heart Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficiency of permanent biventricular pacing using
      three ventricular leads in terms of reduction in adverse cardiac events rates, improvement in
      cardiac capacity and patients' functional status in subjects with congestive heart failure
      and a physiologic (sinus) rhythm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined end-point of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in VO2max and ≥10% in 6MWD.</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of major adverse cardiovascular events (hospitalization for exacerbated HF requiring modification of pharmacotherapy, heart transplant or death).</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Triple-site group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triple-site resynchronization group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard resynchronization group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard (double-site) resynchronization group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads</intervention_name>
    <description>Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)</description>
    <arm_group_label>Standard resynchronization group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Triple-site cardiac resynchronization</intervention_name>
    <description>Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)</description>
    <arm_group_label>Triple-site group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or more,

          -  Congestive heart failure (HF) in NYHA class III-IV within last 90 days despite optimal
             medical treatment,

          -  Left ventricular ejection fraction (EF) &lt;=35% measured with echocardiography,

          -  Sinus rhythm &gt;90% of the time in 24-h Holter monitoring 1-3 days prior to
             randomization,

          -  Inter- or intraventricular mechanical dyssynchrony ≥40ms measured with pulse Doppler
             and tissue Doppler echocardiography,

          -  Optimal pharmacotherapy during the last 90 days,

          -  Signed informed, written consent.

        Exclusion Criteria:

          -  Pregnancy or breastfeeding,

          -  Unstable HF requiring hospitalization with intravenous inotropic drugs within last 90
             days,

          -  Myocardial infarction, percutaneous/surgical revascularization or any cardiosurgical
             procedure within 90 days prior to randomization,

          -  Stroke within last 90 days,

          -  History of chronic or persistent atrial fibrillation, flutter, tachycardia,

          -  Acute myocarditis,

          -  Implanted previously pacemaker, ICD or CRT-device,

          -  Participation in a concurrent trial that could confuse the results of this study,

          -  Mechanical right heart valve,

          -  Prior heart transplant,

          -  Valvular disease that is indication for valve surgery,

          -  Coronary heart disease if percutaneous or surgical revascularization is indicated and
             possible,

          -  Any state, apart from HF, that limits the estimated survival time to &lt;1 year,

          -  Unwillingness or inability to understand the nature of the study, to participate or to
             give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radosław Lenarczyk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Cardiology, Silesian Medical University, Silesian Center for Heart Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Kalarus, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>First Department of Cardiology, Silesian Medical University, Silesian Center for Heart Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Department of Cardiology, Silesian Medical University, Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Lenarczyk R, Kowalski O, Kukulski T, Pruszkowska-Skrzep P, Sokal A, Szulik M, Zielińska T, Kowalczyk J, Pluta S, Sredniawa B, Musialik-Łydka A, Kalarus Z. Mid-term outcomes of triple-site vs. conventional cardiac resynchronization therapy: a preliminary study. Int J Cardiol. 2009 Mar 20;133(1):87-94. doi: 10.1016/j.ijcard.2007.12.009. Epub 2008 Feb 19.</citation>
    <PMID>18242737</PMID>
  </reference>
  <reference>
    <citation>Lenarczyk R, Kowalski O, Kukulski T, Szulik M, Pruszkowska-Skrzep P, Zielinska T, Kowalczyk J, Pluta S, Duszanska A, Sredniawa B, Musialik-Lydka A, Kalarus Z. Triple-site biventricular pacing in patients undergoing cardiac resynchronization therapy: a feasibility study. Europace. 2007 Sep;9(9):762-7. Epub 2007 Jul 13.</citation>
    <PMID>17631515</PMID>
  </reference>
  <reference>
    <citation>Leclercq C, Gadler F, Kranig W, Ellery S, Gras D, Lazarus A, Clémenty J, Boulogne E, Daubert JC; TRIP-HF (Triple Resynchronization In Paced Heart Failure Patients) Study Group. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol. 2008 Apr 15;51(15):1455-62. doi: 10.1016/j.jacc.2007.11.074.</citation>
    <PMID>18402900</PMID>
  </reference>
  <reference>
    <citation>Lenarczyk R, Kowalski O, Sredniawa B, Pruszkowska-Skrzep P, Pluta S, Sokal A, Kukulski T, Stabryła-Deska J, Woźniak A, Kowalczyk J, Zielińska T, Mazurek M, Streb W, Zembala M, Kalarus Z. Triple-site versus standard cardiac resynchronization therapy study (TRUST CRT): clinical rationale, design, and implementation. J Cardiovasc Electrophysiol. 2009 Jun;20(6):658-62. doi: 10.1111/j.1540-8167.2008.01394.x.</citation>
    <PMID>19635069</PMID>
  </reference>
  <results_reference>
    <citation>Lenarczyk R, Kowalski O, Sredniawa B, Pruszkowska-Skrzep P, Mazurek M, Jędrzejczyk-Patej E, Woźniak A, Pluta S, Głowacki J, Kalarus Z. Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing triple-site cardiac resynchronization therapy: a substudy of TRUST CRT randomized trial. J Cardiovasc Electrophysiol. 2012 Nov;23(11):1228-36. doi: 10.1111/j.1540-8167.2012.02375.x. Epub 2012 May 31.</citation>
    <PMID>22651239</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Silesian Centre for Heart Diseases</investigator_affiliation>
    <investigator_full_name>Radoslaw Lenarczyk</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Dyssynchrony</keyword>
  <keyword>Cardiac resynchronization</keyword>
  <keyword>Triple-site pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

